Evaluation of safety and immunogenicity of receptor-binding domain-based COVID-19 vaccine (Corbevax) to select the optimum formulation in open-label, multicentre, and randomised phase-1/2 and phase-2 clinical trials - The Lancet

[unable to retrieve full-text content]

Evaluation of safety and immunogenicity of receptor-binding domain-based COVID-19 vaccine (Corbevax) to select the optimum formulation in open-label, multicentre, and randomised phase-1/2 and phase-2 clinical trials  The Lancet

Comments

Popular posts from this blog

180+ chief medical officers to know | 2025

Primary Care - North Greece Internal Medicine & Pediatrics

Recommended Adult Immunization Schedule, United States, 2020* | Annals of Internal Medicine